Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue

Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue

Market drugs, such as Food and Drug Administration (FDA) or European Medicines Agency (EMA)-approved drugs for specific indications provide opportunities for repurposing for newer therapeutics. This potentially saves resources invested in clinical trials that verify drug safety and tolerance in huma...

Full description

Bibliographic Details
Main Authors: Lakshmi Prabhu, Matthew Martin, Lan Chen, Özlem Demir, Jiamin Jin, Xiumei Huang, Aishat Motolani, Mengyao Sun, Guanglong Jiang, Harikrishna Nakshatri, Melissa L. Fishel, Steven Sun, Ahmad Safa, Rommie E. Amaro, Mark R. Kelley, Yunlong Liu, Zhong-Yin Zhang, Tao Lu
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2023-01-01
Series:Genes and Diseases
Subjects:
Cancer Research
NF-kB
Pharmacology
PRMT5
PRMT5 inhibitors
Online Access:http://www.sciencedirect.com/science/article/pii/S2352304222000939

Internet

http://www.sciencedirect.com/science/article/pii/S2352304222000939

Similar Items